Michael G. Kauffman
2020
In 2020, Michael G. Kauffman earned a total compensation of $3.9M as Chief Executive Officer at Karyopharm Therapeutics, a 22% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $348,750 |
|---|---|
| Option Awards | $1,920,899 |
| Salary | $625,624 |
| Stock Awards | $1,029,886 |
| Other | $11,880 |
| Total | $3,937,039 |
Kauffman received $1.9M in option awards, accounting for 49% of the total pay in 2020.
Kauffman also received $348.8K in non-equity incentive plan, $625.6K in salary, $1M in stock awards and $11.9K in other compensation.
Rankings
In 2020, Michael G. Kauffman's compensation ranked 2,897th out of 13,090 executives tracked by ExecPay. In other words, Kauffman earned more than 77.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,897 out of 13,090 | 78th |
Division Manufacturing | 1,117 out of 5,620 | 80th |
Major group Chemicals And Allied Products | 414 out of 2,253 | 82nd |
Industry group Drugs | 358 out of 1,953 | 82nd |
Industry Pharmaceutical Preparations | 263 out of 1,458 | 82nd |
Source: SEC filing on April 7, 2021.
Kauffman's colleagues
We found two more compensation records of executives who worked with Michael G. Kauffman at Karyopharm Therapeutics in 2020.
News
Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
April 8, 2022
Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
April 7, 2021
Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
April 9, 2020
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
April 19, 2019